Effects of Isorhamnetin on Diabetes: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Subjects: Medicine, Research & Experimental | Integrative & Complementary Medicine | Endocrinology & Metabolism
Contributor:
Hiroko Isoda

Diabetes mellitus, especially type 2 (T2DM), is a major public health problem globally. DM is characterized by high levels of glycemia and insulinemia due to impaired insulin secretion and insulin sensitivity of the cells, known as insulin resistance. T2DM causes multiple and severe complications such as nephropathy, neuropathy, and retinopathy causing cell oxidative damages in different internal tissues, particularly the pancreas, heart, adipose tissue, liver, and kidneys. Isorhamnetin, a plant flavonoid, has long been studied for its potential anti-diabetic effects. Isorhamnetin is a monomethoxyflavone or an O-methylated flavonol from the class of flavonoids. It is quercetin in which a methoxy group replaces the hydroxy group at position 3’. Some isorhamnetin derivatives are present in nature, such as isorhamnetin 3-O-β-d-glucopyranoside, isorhamnetin 3-O-neohesperidoside, and isorhamnetin 3-O-rutinoside from Calendula officinalis L.. Isorhamnetin presents significant biological properties such as antioxidant, anticancer, antimicrobial, antiviral, anti-inflammatory and anti-diabetic effects.

  • isorhamnetin
  • quercetin
  • biological activities
  • diabetes
  • molecular pathways

1. General Overview of Biological Activities of Isorhamnetin

Oxidative stress is an endogenous and exogenous process that plays a role in aging. Oxidative stress occurs due to dysregulation in the antioxidant defences resulting from the imbalanced production of ROS and nitrogen species [1]. Several researchers have shown that long-term exposure to free radicals contributes to the development of chronic diseases, such as cancer [2], diabetes [3], cardiovascular problems [4], and neurodegenerative disease [5]. Therefore, the study of the biological activities of isorhamnetin can be initiated by investigating the involvement of this molecule in the antioxidant phenomenon. Isorhamnetin belongs to the flavonol class known for its antioxidant potential [6][7]. Moreover, several studies have shown that this flavonol has remarkable antioxidant activity, scavenging DPPH radical and ABTS radical, and can inhibit lipid peroxidation [8][9][10]. Wu et al. showed that isorhamnetin and isorhamnetin-3-glucuronide could inhibit the human breast cancer MCF-7 cell proliferation [11]. Wei et al. proved that isorhamnetin inhibits the proliferation of a cervical cancer cell line HeLa [12]. The mechanism of the anti-proliferative effect of isorhamnetin was thoroughly related to cell cycle arrest at the G2/M stage by the activation of the ATM-Chk2 pathway. Li and colleagues revealed that isorhamnetin could also inhibit the growth of the gefitinib resistant PC9 cells (PC9-IR) by downregulating BCL-2 gene expression and PCNA protein expression, inhibiting DNA synthesis and upregulating P53, BAX and CASP3 gene expression [13]. Along with this, Aonuma et al. [14] demonstrated that isorhamnetin might efficiently suppress hypertrophy and fibrosis induced by angiotensin II in cardiac tissue by regulating transforming growth factor (TGF-β) pathways. Furthermore, it might have appreciated properties on potential clinical consequences of cardiovascular diseases by the renin-angiotensin system regulation. Isorhamnetin exerted a neuroprotective effect against ischemic injury in mice by reducing infarct volume and Casp3 activity (a biomarker of apoptosis) and improving neurological function repossession. Likewise, the mice treated with this flavonol showed decreased cerebral edema, enhanced blood–brain barrier function, and upregulated gene expression of tight junction proteins, including Ocln, Zo-1, and Cldn-5 [15]. Ishola et al. reported that isorhamnetin ameliorates scopolamine-induced spatial and non-spatial learning and memory impairment in vivo [16]. Likewise, it could reduce malondialdehyde (MDA) and nitrite production by increasing glutathione (GSH) level, SOD, and CAT activities in the prefrontal cortex and hippocampus. The anti-inflammatory effect of isorhamnetin and related mechanisms have been widely studied [17]. Yang et al. [18] demonstrated that isorhamnetin could alleviate LPS-induced acute lung injury by inhibiting Cox-2 expression in male BALB/c mice [19]. Similarly, the in vivo study of Dou et al. [20] showed that it could alleviate bowel disease by activating PXR and promoting the upregulation of PXR-mediated metabolism of probiotics and the downregulation of nuclear factor-kappa B (NF-κB) signal transduction [20].
Furthermore, isorhamnetin has been reported to prevent pulmonary tuberculosis [21]. Additionally, it may ameliorate acute kidney injury by inhibiting the NF-κB signaling pathway activation [22]. Additionally, isorhamnetin exhibits anti-thrombus [23], antihypertensive [24], anti-inflammatory [25], anti-osteoporosis [26], antiplatelet activity [27], hepatoprotective [28], and anti-hypoxia [29] effects. It has also been shown that isorhamnetin could boost innate immunity [30]. However, we have not found a wide range of publications that confirm antimicrobial and antiviral activities of isorhamnetin. Still, some studies reported bactericidal effects of plant extracts containing isorhamnetin or its derivatives [31][32][33]. Antiviral activities of isorhamnetin were observed against influenza [34], SARS-CoV-2 spike [35], and herpes simplex [36] (see the summary in Figure 1). In summary, this interesting molecule is an immense source of biological activities. More than what we have mentioned, it is endowed with a critical anti-diabetic activity that we study in the next section of this review.
Ijms 23 00704 g003 550
Figure 1. Overview of biological activities of isorhamnetin. NB. Circles do not represent any hierarchical relationship.

2. Anti-Diabetic Effect of Isorhamnetin

Isorhamnetin has been reported to alleviate shared metabolic complications in type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), but until the present, it is more aligned with T2DM. For example, Matboli et al. showed that isorhamnetin used at three different doses (10, 20, 40 mg/kg for 3 weeks) possessed anti-diabetic action by regulating the insulin pathway at the microscopic, molecular and protein levels in the streptozotocin/high fat diet-induced T2DM rat models [37]. Authors in this study concluded that isorhamnetin could be used as an alternative and/or potential complementary treatment in T2DM through modulation of insulin resistance signaling pathway-related gene expression. However, regarding T1DM, the effect of isorhamnetin is not yet well studied with in vitro and in vivo models.

2.1. General Overview on Diabetes and Its Link with Metabolic Syndrome

Metabolic syndrome is a constellation of cardiometabolic risk factors first described 90 years ago [38]. In 1988, the notion of syndrome X appeared [39]. It includes abdominal obesity, insulin resistance, glucose intolerance (or hyperglycemia), hypertension, and dyslipidemia. The combination of these risk factors is linked to an increased risk of developing T2DM and cardiovascular diseases. Diabetes mellitus (DM) is a prevalent metabolic disease characterized by abnormally elevated blood glucose levels. It is classified into type 1 (T1DM) and type 2 (T2DM). The first category of diabetes (T1DM) is typically associated with failure in insulin production resulting from the destruction of pancreatic β-cells by T-cell-mediated autoimmunity. However, T2DM is more specific to insulin resistance and function [40]. The causes of metabolic syndrome are generally poorly understood but involve genetic factors linked to the environment. Among the genetic factors, one can quote those determining the corpulence, the distribution of the fatty mass, the hyperinsulinemia, and various metabolisms (lipoproteins) [41]. The constitutive elements of these factors tend to derive from multivalent logic. The environmental factors, the sedentary lifestyle, smoking, excess calories provided in the form of lipids, and added sugars, in particular, are better known. Many other factors have been recently discovered, such as the presence of inflammatory cells in adipose tissue and alterations in the secretion of adipokines [41]. It is, therefore, necessary to find an adequate and safe treatment given the severe consequences of this disease on health, including diabetic nephropathy, retinopathy, neuropathy, cardiovascular diseases, and diabetic foot ulcer [40].

2.2. Effect of Isorhamnetin on Associated Metabolic Pathways

Several in vitro and in vivo studies showed that isorhamnetin might modulate carbohydrate metabolism and exhibit anti-diabetic activities by involving different mechanisms. Researchers have suggested that isorhamnetin promotes carbohydrate metabolism from the stages of digestion and intestinal absorption [42], improves glucose uptake by the liver and muscles [43][44], protects the pancreatic β-cells and alleviates insulin secretion impairment [45]. In addition, isorhamnetin regulates adipose tissue differentiation, growth and maturation [46]. For anti-diabetic potential, researchers have investigated isorhamnetin isolated from different medicinal plants. In Table 1, we have listed the plant sources and extraction procedures of isorhamnetin that regulated diabetes-associated different intracellular signaling pathways. In the rest of this review, we will try to explain the impact of this molecule and its metabolic precursor (quercetin) [47] on the diabetes-associated mechanisms.
Table 1. Isorhamnetin resources cited in the current review.
Plant Sources Extraction Methods Action Modes References
Vaccinium vitis-idaea Fractionation guided
80% ethanol > ethyl acetate > water		 Enhances muscle cell glucose uptake [48]
Nitraria retusa Maceration in water-ethanol solution Modulation of lipogenesis–lipolysis balance [49]
Nitraria retusa Maceration in water-ethanol solution 3T3-L1 preadipocyte differentiation regulation [50]
Corchorus olitorius Soxhlet extraction with methanol, the residue from the above soluble extraction was hydrolyzed directly with 200 mL of 4 M NaOH solution. Then, the mixture was adjusted to pH 2 with concentrated HCl and the bound phytochemicals were extracted with ethyl acetate. - α-Amylase inhibition
- α-Glucosidase inhibition
- Angiotensin I converting enzyme (ACE) inhibition
- Degradation of deoxyribose		 [44]
Salicornia herbacea Fractionation guided ethanol under reflux > ethyl
acetate ethyl acetate fraction was eluted on a silica gel chromatography by gradient elution with chloroform and methanol		 - α-Glucosidase
- Regulating the expression of ERK, PI3K, AKT, IRS-2, and PDX-1		 [45]
Eruca sativa Extraction with ethanol by the accelerated solvent extractor, at 50 °C, 1500 psi for 20 min Activation of PPAR-α and suppression of inflammatory cytokines [51]
Oenanthe javanica Isorhamnetin was isolated from the aerial part of O. javanica and its purity was higher than 95.0% Attenuation of fibrosis in rat hepatic stellate cells via inhibition of ERK signaling pathway [52]

2.2.1. Effect of Isorhamnetin on Glucose Transporters

Glucose transporters (GLUT) are a large group of membrane proteins that transport glucose from epithelial cells to blood and from blood to cells passing the intestinal barrier in the gradient direction by passive transport. Some of them are insulin-dependent, notably GLUT4. It is a major insulin-regulated glucose transporter and coordinator of insulin action in adipose. In fact, it is well established that insulin, which enhances glucose uptake, also stimulates the recruitment of GLUT4 to the cell membrane of insulin-sensitive tissue. In a study underlying the anti-diabetic properties of quercetin and isorhamnetin, the authors proved that physiological concentrations of isorhamnetin promoted GLUT4 translocation to the plasma membrane in L6 myotubes through different mechanisms without altering GLUT4 expression [44]. In fact, isorhamnetin could activate the JAK-STAT signaling pathway at 1 nM and 10 nM, allowing glucose transporter translocation induction. JAK-STAT is a signal transduction system composed of a transmembrane receptor, coupled to a Janus Kinase (JAK) enzyme and a STAT-type protein. When a ligand binds to the receptor, it changes its conformation, activating the enzyme JAK, which phosphorylates the STAT protein, inducing a transduction cascade and activating transcription of specific genes [53]. In an in silico study, Selvaraj [54] showed that certain flavonoids, including isorhamnetin, can strongly interact with the active site of GLUT4 protein through H-bond interaction. This finding lets us look for the influence of this molecule on glucose transporters, particularly GLUT 4. By comparison, quercetin stimulates the insulin and AMPK-dependent pathway in the same L6 cells. In fact, Eid et al. have shown that an 18 h treatment of cultured rat L6 skeletal muscle cells with a dose of 50 µM quercetin could stimulate AMPK and increase GULT4 translocation [55]. Likewise, quercetin demonstrated divergent effects on insulin-mediated GLUT4 translocation in adipocytes under basal and insulin-resistant conditions related to its regulation of AMPK activity [56]. Moreover, Eid et al. confirmed that quercetin aglycone, extracted from Vaccinium vitis berries, could enhance muscle cell glucose uptake [48]. Guided fractionation of berry extract based on glucose uptake in muscle cells demonstrated that quercetin-3-O-glycosides were the main active compounds. At 50 μM, these compounds enhanced basal glucose uptake by up to 59% following an 18 h treatment, an effect significantly greater than that of 100 nM insulin.

2.2.2. Effect of Isorhamnetin on Peroxisome Proliferator-Activated Receptors (PPARs)

PPARs belong to the transcription nuclear receptor factors class II family with an important action in the glucose and lipid metabolism regulation [57]. They are expressed in various cell types: pancreatic cells, hepatic cells, and adipose cells, thus controlling a wide range of biological processes by the modulation of related genes’ expressions [58]. In mammalian cells, three isoforms are present: PPARα, PPARβ/δ and PPARγ, which regulate genes implicated in glucose and lipid transport, synthesis and fatty acid oxidation [59][60]. Many clinical studies are targeting PPARs for metabolic disorders and diabetes treatments. Thiazolidinediones (TZDs: pioglitazone and rosiglitazone) are a class of oral anti-diabetic drugs that reduce high blood sugar levels and improve the lipid profile of T2DM patients. A huge number of hypotheses suggest that the anti-diabetic effect of TZDs is exerted via PPARγ. Fibrates that target PPARα have also been used to treat hyperlipidemia and diabetes. Isorhamnetin has been reported to exert similar effects as the mentioned drugs, mainly as PPARs antagonists or agonists [51], which ameliorates metabolic complications induced by a high-fat diet or leptin deficiency [61]. Pre-adipocyte cell line model 3T3-L1 cells are widely used in obesity and diabetes research [62][63]. Obesity-induced diabetes is characterized by hypertrophy and hyperplasia of adipocytes. Pretreatment of 3T3-L1 cells with different doses of isorhamnetin could inhibit adipocyte differentiation by decreasing triglyceride (TG) accumulation and glycerol-3-phosphate dehydrogenase (GPDH) activity [46]. At the molecular level, isorhamnetin could also regulate the mRNA expression of the major adipocyte markers, mainly the transcription factors PPARγ and CCAAT/enhancer-binding protein-α (C/EBPα), the master co-working regulators of adipogenesis and cell differentiation [46][64]. These findings were also concordant with studies revealing that Nitraria retusa isorhamnetin-rich extract could reduce the fat accumulation in 3T3-L1 adipocytes in a dose-dependent manner [50]. The single-molecule isorhamnetin could also significantly inhibit the differentiation rate of 3T3-L1 cells, leading to reducing lipid droplet content by reducing cell size and number. In addition, oral administration of the Nitraria retusa extract could regulate PPARγ and lipogenic enzymes target genes LPL and FAS [49]. Importantly, a recent study revealed that isorhamnetin could significantly reduce fat amount in animal body via PPARα-dependent pathway [65].

2.2.3. Effect of Isorhamnetin on Hepatic Enzymes

The liver is an organ that plays a key role in carbohydrate homeostasis [66]. Beyond the micro and macrovascular complications of diabetes, the T2DM patient presents more certain hepatic complications with, in the first place, hepatic steatosis. In T2DM, the risk of progression to fibrosis and hepatic inflammation is greater [67], exposing a certain number of diabetic patients to significant clinical consequences, particularly with hepatocarcinoma [68]. In parallel, hepatic complications in diabetic patients have been associated with a higher risk of cardiovascular events, which may have practical consequences in terms of optimization of cardiovascular prevention [69]. We focus on the most important liver complications related to diabetes: fatty liver diseases, hepatic fibrosis, and hepatocellular carcinoma (HCC).

Non-Alcoholic Steatohepatitis

Fatty liver disease or non-alcoholic steatohepatitis (NASH) represents a potential hepatic complication. It is characterized as an abnormal accumulation of TGs inside liver cells. In type 2 diabetes, insulin resistance leads to the accumulation of toxic fatty acids. When this accumulation occurs in liver cells it causes non-alcoholic fatty liver disease (NAFLD) and in severe forms steatosis or NASH [67][70]. Ganbold et al. have shown that isorhamnetin ameliorated hepatic steatosis and fibrosis in a NASH mouse model exhibits similar features of human NASH [43]. In fact, compared to the control mouse group, liver samples from the NASH-induced group showed acute fat accumulation overtaking 37% of the oil red O positive area. However, isorhamnetin treatment in the NASH group could reduce oil red O stained area to 22%. In addition, isorhamnetin treatment alleviated NASH-induced gene expression alteration. The authors have shown that isorhamnetin efficiently improved the altered lipid metabolic process in NASH and inhibited de novo lipogenesis.

Hepatic Fibrosis

Hepatic fibrosis is excessive scarring resulting from the build-up of connective tissue in the liver. It is caused by excessive production and/or insufficient degradation of extracellular matrix. There are many causes of liver fibrosis. Among them is NASH origin. When there is resistance to insulin, fatty acids build up in the liver, causing toxicity and inflammation. This is accompanied by the production of cytokines and reactive oxygen species. In fibrosis, cytokines are responsible for the activation of hepatic stellate cells (HSCs) and will activate an excessive production of collagen fibers [71][72]. The trigger is chronic aggression, especially in the event of an inflammatory component [71]. TGF-β is a crucial mediator of HSC activation and extracellular matrix accumulation, leading to fibrosis [73]. Therefore, blocking this pathway could be a potential strategy for liver fibrosis [74]. In this context, Yang et al. demonstrated that isorhamnetin inhibited HSC activation and prevented TGF-β-induced expression of fibrogenic genes, including α-SMA, PAI-1, and COL1A1 [19]. In fact, the authors revealed that the inhibitory effect of this flavonol was a result of the canonical TGF-β/Smad signaling pathway inhibition. Additionally, isorhamnetin activated Nrf2-ARE signaling and suppressed TGF-β-mediated ROS production, which also contributed to the inhibition of fibrogenic gene expression. Furthermore, isorhamnetin significantly suppressed carbon tetrachloride (CCl4)-induced fibrosis in mice. Liu et al. also showed that isorhamnetin could alleviate CCl4 and bile duct ligation (BDL)-induced liver fibrosis by inhibiting TGF-β1 production and HSC activation [75]. Likewise, Lee et al. demonstrated that isorhamnetin, extracted from Oenanthe javanica, could reduce fibrosis in rat HSCs by blocking the extracellular signal regulated kinase (ERK) signaling pathway and inhibiting the proliferation and collagen synthesis of HSC-T6 cells [52]. In fact, pretreatment of HSC-T6 cells with this flavonol repressed serum-induced ERK phosphorylation, the same way as a MEK inhibitor (PD98059).

Hepatocellular Carcinoma

Hepatocellular carcinoma is often discovered late at the metastasis stage (in 64% of cases); the most frequent secondary locations are the lung, lymph nodes, kidneys, and adrenal glands [76]. As mentioned above, with the high accumulation of fatty acid in liver cells, physiological disturbances appear over time such as NASH, then inflammation (with production of cytokines and ROS), then in more advanced cases cirrhosis and in severe forms carcinoma [77][78]. The role of isorhamnetin is deduced by its anti-tumor potential activities. Isorhamnetin, extracted from Hippophae rhamnoides L., showed potent anti-tumor activity in hepatocellular carcinoma BEL-7402 cells, exerting strong cytotoxicity with IC50 at the concentration of 74.4 ± 1.13 µg/mL and 72 h incubation [79]. Cytotoxicity of this flavonol on cancer cells depends on isorhamnetin cellular accumulation. Instead, the pibenzimol hydrochloride staining of isorhamnetin-treated cells displayed condensed and fragmented nuclei and apoptotic bodies. Furthermore, flow cytometry analysis used to evaluate cell cycle progression and differentiate between apoptosis or necrosis, revealed that 13.77% of isorhamnetin-treated BEL-7402 cells (with 50 µg/mL for 48 h) appeared in the hypodiploid peak. Similar work by Wei et al. reported that isorhamnetin inhibited the cell cycle progression of the cervical cancer cell line HeLa, by arresting the G2/M phase via activating the ataxia-telangiectasia mutated Chk2 pathway [20]. In another work and by making a comparison, isorhamnetin-3-O-glucoside, quercetin 3-O-rhamnoside-7-O-glucoside and kaempferol-3-O-glucoside-7-O-rhamnoside, extracted from Cleome droserifolia, reduced HepG2, a liver hepatocellular carcinoma cell, cell viability and anchorage-independent cell growth in a dose- and time-dependent manner but with a highest effect with the quercetin derivative. Furthermore, they exhibited a reduced migration capacity of HepG2 cells [80].

2.2.4. Effect of Isorhamnetin on Pancreatic β-Cell Dysfunction

Insulin is a hormone naturally secreted by the body that helps our cells, particularly muscle cells, liver cells, adipose cells, and brain cells, absorb glucose from food to be converted into energy for all biological processes and functions [81][82]. In normal conditions, insulin is secreted by pancreatic β-cells, then released into the bloodstream. β-cell dysfunction is characterized by impaired insulin secretion, the critical feature of T2DM, both in its onset and progression [83]. Metabolic stress-induced β-cell dysfunction in T2DM can also be associated with high levels of saturated fats in obesity, leading to increased inflammation and oxidative stress within β-cells. Therefore, impairment of insulin secretion is more severe than insulin resistance [84]. Taken together, new anti-diabetic therapeutic strategies are needed to prevent or recover pancreatic β-cell dysfunction. In this context, Wang et al. suggested that isorhamnetin, derived from Vernonia anthelmintica herb, could suppress the proliferation of pancreatic cancer cells (colorectal adenocarcinoma cell line) via arresting the cell cycle in the S phase, which may be an alternative way to prevent pancreatic carcinoma and its metabolic complications [85]. Consistently, another report has shown that isorhamnetin and a glycosylated form of isorhamnetin (isolated from Salicornia herbacea plant) could promote glucose-stimulated insulin secretion in insulin-secreting rat insulinoma (INS-1) pancreatic β-cells without affecting cell viability [45]. Moreover, it could stimulate insulin secretion via phosphorylation of total ERK, insulin receptor substrate-2 (IRS-2), phosphatidylinositol 3-kinase (PI3K), Akt, and activated pancreatic and duodenal homeobox-1 (PDX-1) [45]. The enhancement of these markers may alleviate the pancreatic cell dysfunction causing diabetes.
Furthermore, Grdović et al. reported that isorhamnetin originated from the Castanea sativa plant species has a protective effect on streptozotocin-induced oxidative damage and β-cell apoptotic death [86]. This beneficial effect was correlated strongly to the antioxidant potential of this molecule by alleviating the cellular biomarkers of oxidative stress, i.e., MDA and intracellular GSH levels, and enhancing the activities of antioxidant enzymes SOD and CAT. The effect was also confirmed at the molecular level by the decreased NF-kB transcription factor stimulated by cell oxidative stress, and thus suggestive of a protective effect within β-cells. Consistently, quercetin, which is metabolized in isorhamnetin, could reduce glucose levels by ameliorating insulin secretion in the streptozotocin-induced type 1 diabetes model in rats [87]. In the same animal model, quercetin showed a protective effect on β-cell integrity by reducing oxidative stress markers [88]. It could also regenerate the islets in pancreatic cells [89].

2.2.5. Effect of Isorhamnetin on NF-κB

NF-κB is a protein of the superfamily of transcription factors involved in the immune and cellular stress responses and is considered as the major mediator of the secretion of inflammatory markers such as cytokines, chemokines, and different key enzymes [86][90][91]. The role of NF-κβ in the pathophysiology of diabetes and its linked vascular complications has been investigated [92]. Hyperglycaemia activates this nuclear factor that in turn induces the secretion and over-expression of pro-inflammatory cytokines, mainly TNF-α, interleukins, TGF-β, and Bcl2, causing vascular complications such as neuropathy, nephropathy, retinopathy, and cardiomyopathy [93]. Many experimental investigations on the preventive effect of flavonols on diabetes-induced vascular dysfunction have demonstrated that isorhamnetin could inhibit the activation of NF-κβ through inducing the activity of pancreatic antioxidant enzymes [94]. Another study reported the inhibitory effect of isorhamnetin on iNOS expression and NO production in activated macrophages, leading to the blocking of NF-κβ [95]. Moreover, Qiu et al. have studied the renoprotective effect of the flavonol isorhamnetin in the T2DM rat model through the modulation of the NF-κβ signaling pathway [22]. Authors have shown that this molecule inhibited the NF-κB signaling activity by increasing the production of NF-κB p65, phospho-NF-κB p65, and phospho-IκBα and inflammatory mediators TNF-α, IL-1β, IL-6, ICAM-1, and TGF-β1, as well as decreasing the NF-κB p65 DNA-binding activity. In addition, it could alleviate oxidative cell stress by regulating MDA and SOD levels, leading to recovery of renal damages in diabetic rats.

This entry is adapted from the peer-reviewed paper 10.3390/ijms23020704

References

  1. Liguori, I.; Russo, G.; Curcio, F.; Bulli, G.; Aran, L.; Della-Morte, D.; Gargiulo, G.; Testa, G.; Cacciatore, F.; Bonaduce, D. Oxidative stress, aging, and diseases. Clin. Interv. Aging 2018, 13, 757.
  2. Hayes, J.D.; Dinkova-Kostova, A.T.; Tew, K.D. Oxidative stress in cancer. Cancer Cell 2020, 38, 167–197.
  3. Wei, W.; Liu, Q.; Tan, Y.; Liu, L.; Li, X.; Cai, L. Oxidative stress, diabetes, and diabetic complications. Hemoglobin 2009, 33, 370–377.
  4. Madamanchi, N.R.; Vendrov, A.; Runge, M.S. Oxidative stress and vascular disease. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 29–38.
  5. Barnham, K.J.; Masters, C.L.; Bush, A.I. Neurodegenerative diseases and oxidative stress. Nat. Rev. Drug Discov. 2004, 3, 205–214.
  6. De Souza Farias, S.A.N.; da Costa, K.S.; Martins, J.o.B. Analysis of Conformational, Structural, Magnetic, and Electronic Properties Related to Antioxidant Activity: Revisiting Flavan, Anthocyanidin, Flavanone, Flavonol, Isoflavone, Flavone, and Flavan-3-ol. ACS Omega 2021, 6, 8908–8918.
  7. Ronsisvalle, S.; Panarello, F.; Longhitano, G.; Siciliano, E.A.; Montenegro, L.; Panico, A. Natural flavones and flavonols: Relationships among antioxidant activity, glycation, and metalloproteinase inhibition. Cosmetics 2020, 7, 71.
  8. Seo, S.; Seo, K.; Ki, S.H.; Shin, S.M. Isorhamnetin inhibits reactive oxygen species-dependent hypoxia inducible factor (HIF)-1α accumulation. Biol. Pharm. Bull. 2016, 39, 1830–1838.
  9. Pengfei, L.; Tiansheng, D.; Xianglin, H.; Jianguo, W. Antioxidant properties of isolated isorhamnetin from the sea buckthorn marc. Plant Foods Hum. Nutr. 2009, 64, 141–145.
  10. Zuo, A.; Yanying, Y.; Li, J.; Binbin, X.; Xiongying, Y.; Yan, Q.; Shuwen, C. Study on the relation of structure and antioxidant activity of isorhamnetin, quercetin, phloretin, silybin and phloretin isonicotinyl hydrazone. Free Radic. Antioxid. 2011, 1, 39–47.
  11. Wu, Q.; Kroon, P.A.; Shao, H.; Needs, P.W.; Yang, X. Differential effects of quercetin and two of its derivatives, isorhamnetin and isorhamnetin-3-glucuronide, in inhibiting the proliferation of human breast-cancer MCF-7 cells. J. Agric. Food Chem. 2018, 66, 7181–7189.
  12. Wei, J.; Su, H.; Bi, Y.; Li, J.; Feng, L.; Sheng, W. Anti-proliferative effect of isorhamnetin on HeLa cells through inducing G2/M cell cycle arrest. Exp. Ther. Med. 2018, 15, 3917–3923.
  13. Li, C.; Yang, X.; Hu, J.-B.; Liao, J.-Z. Isorhamnetin suppresses the growth of gefitinib resistant human lung cancer PC9 cells. Her. Med. 2012, 31, 831–834.
  14. Aonuma, K.; Ferdousi, F.; Xu, D.; Tominaga, K.; Isoda, H. Effects of isorhamnetin in human amniotic epithelial stem cells in vitro and its cardioprotective effects in vivo. Front. Cell Dev. Biol. 2020, 8, 578197.
  15. Zhao, J.-J.; Song, J.-Q.; Pan, S.-Y.; Wang, K. Treatment with isorhamnetin protects the brain against ischemic injury in mice. Neurochem. Res. 2016, 41, 1939–1948.
  16. Ishola, I.O.; Osele, M.O.; Chijioke, M.C.; Adeyemi, O.O. Isorhamnetin enhanced cortico-hippocampal learning and memory capability in mice with scopolamine-induced amnesia: Role of antioxidant defense, cholinergic and BDNF signaling. Brain Res. 2019, 1712, 188–196.
  17. Seo, K.; Yang, J.H.; Kim, S.C.; Ku, S.K.; Ki, S.H.; Shin, S.M. The antioxidant effects of isorhamnetin contribute to inhibit COX-2 expression in response to inflammation: A potential role of HO-1. Inflammation 2014, 37, 712–722.
  18. Yang, B.; Li, X.-P.; Ni, Y.-F.; Du, H.-Y.; Wang, R.; Li, M.-J.; Wang, W.-C.; Li, M.-M.; Wang, X.-H.; Li, L. Protective effect of isorhamnetin on lipopolysaccharide-induced acute lung injury in mice. Inflammation 2016, 39, 129–137.
  19. Yang, J.H.; Kim, S.C.; Kim, K.M.; Jang, C.H.; Cho, S.S.; Kim, S.J.; Ku, S.K.; Cho, I.J.; Ki, S.H. Isorhamnetin attenuates liver fibrosis by inhibiting TGF-β/Smad signaling and relieving oxidative stress. Eur. J. Pharmacol. 2016, 783, 92–102.
  20. Dou, W.; Zhang, J.; Li, H.; Kortagere, S.; Sun, K.; Ding, L.; Ren, G.; Wang, Z.; Mani, S. Plant flavonol isorhamnetin attenuates chemically induced inflammatory bowel disease via a PXR-dependent pathway. J. Nutr. Biochem. 2014, 25, 923–933.
  21. Jnawali, H.N.; Jeon, D.; Jeong, M.-C.; Lee, E.; Jin, B.; Ryoo, S.; Yoo, J.; Jung, I.D.; Lee, S.J.; Park, Y.-M. Antituberculosis activity of a naturally occurring flavonoid, isorhamnetin. J. Nat. Prod. 2016, 79, 961–969.
  22. Qiu, S.; Sun, G.; Zhang, Y.; Li, X.; Wang, R. Involvement of the NF-κB signaling pathway in the renoprotective effects of isorhamnetin in a type 2 diabetic rat model. Biomed. Rep. 2016, 4, 628–634.
  23. Ibarra, M.; Pérez-Vizcaíno, F.; Cogolludo, A.; Duarte, J.; Zaragozá-Arnáez, F.; López-López, J.G.; Tamargo, J. Cardiovascular effects of isorhamnetin and quercetin in isolated rat and porcine vascular smooth muscle and isolated rat atria. Planta Med. 2002, 68, 307–310.
  24. Chang, Z.; Wang, J.l.; Jing, Z.c.; Ma, P.; Xu, Q.b.; Na, J.r.; Tian, J.; Ma, X.; Zhou, W.; Zhou, R. Protective effects of isorhamnetin on pulmonary arterial hypertension: In vivo and in vitro studies. Phytother. Res. 2020, 34, 2730–2744.
  25. Antunes-Ricardo, M.; Gutiérrez-Uribe, J.A.; Martínez-Vitela, C.; Serna-Saldívar, S.O. Topical anti-inflammatory effects of isorhamnetin glycosides isolated from Opuntia ficus-indica. BioMed Res. Int. 2015, 2015, 847320.
  26. Yang, L.; Chen, Q.; Wang, F.; Zhang, G. Antiosteoporotic compounds from seeds of Cuscuta chinensis. J. Ethnopharmacol. 2011, 135, 553–560.
  27. Rodríguez, L.; Badimon, L.; Méndez, D.; Padró, T.; Vilahur, G.; Peña, E.; Carrasco, B.; Vogel, H.; Palomo, I.; Fuentes, E. Antiplatelet Activity of Isorhamnetin via Mitochondrial Regulation. Antioxidants 2021, 10, 666.
  28. Dong, G.-Z.; Lee, J.-H.; Ki, S.H.; Yang, J.H.; Cho, I.J.; Kang, S.H.; Zhao, R.J.; Kim, S.C.; Kim, Y.W. AMPK activation by isorhamnetin protects hepatocytes against oxidative stress and mitochondrial dysfunction. Eur. J. Pharmacol. 2014, 740, 634–640.
  29. Zhang, D.; Lei, J.; Hong, E.-K.; Lu, D.; Yuan, W.; Yang, Z.; Ming, C. Anti-hypoxia effects of the ethanol extract of Oxytropis ochrocephala. Legume Res.-Int. J. 2016, 39, 914–920.
  30. Wang, H.; Zhang, Q.; Cheng, M.L.; Ma, L.; Meng, Q.Z.; Duan, L.; Chen, Y.; Tan, J.W.; Chen, M.; Liang, T.T. Effect of the Miaoyao Fanggan sachet-derived isorhamnetin on TLR2/4 and NKp46 expression in mice. J. Ethnopharmacol. 2012, 144, 138–144.
  31. Rigano, D.; Formisano, C.; Basile, A.; Lavitola, A.; Senatore, F.; Rosselli, S.; Bruno, M. Antibacterial activity of flavonoids and phenylpropanoids from Marrubium globosum ssp. libanoticum. Phytother. Res. 2007, 21, 395–397.
  32. Ren, X.; Bao, Y.; Zhu, Y.; Liu, S.; Peng, Z.; Zhang, Y.; Zhou, G. Isorhamnetin, hispidulin, and cirsimaritin identified in Tamarix ramosissima barks from southern Xinjiang and their antioxidant and antimicrobial activities. Molecules 2019, 24, 390.
  33. Bhattacharya, D.; Ghosh, D.; Bhattacharya, S.; Sarkar, S.; Karmakar, P.; Koley, H.; Gachhui, R. Antibacterial activity of polyphenolic fraction of Kombucha against Vibrio cholerae: Targeting cell membrane. Lett. Appl. Microbiol. 2018, 66, 145–152.
  34. Dayem, A.A.; Choi, H.Y.; Kim, Y.B.; Cho, S.-G. Antiviral effect of methylated flavonol isorhamnetin against influenza. PLoS ONE 2015, 10, e0121610.
  35. Zhan, Y.; Ta, W.; Tang, W.; Hua, R.; Wang, J.; Wang, C.; Lu, W. Potential antiviral activity of isorhamnetin against SARS-CoV-2 spike pseudotyped virus in vitro. Drug Dev. Res. 2021, 82, 1124–1130.
  36. Kim, H.-K.; Kang, B.-J.; Park, K.-J.; Ko, B.-S.; Whang, W.-K. Anti-Herpes Simplex Virus type I (HSV-1) Effect of Isorhamnetin 3-0-beta-D-Glucopyranoside Isolated from Brassica rapa. Yakhak Hoeji 1998, 42, 607–612.
  37. Matboli, M.; Saad, M.; Hasanin, A.H.; Saleh, L.A.; Baher, W.; Bekhet, M.M.; Eissa, S. New insight into the role of isorhamnetin as a regulator of insulin signaling pathway in type 2 diabetes mellitus rat model: Molecular and computational approach. Biomed. Pharmacother. 2021, 135, 111176.
  38. Kylin, E. Studien ueber das Hypertonie-Hyperglyka “mie-Hyperurika” miesyndrom. Zent. Inn. Med. 1923, 44, 105–127.
  39. Reaven, G.M. Role of insulin resistance in human disease. Diabetes 1988, 37, 1595–1607.
  40. Tan, S.Y.; Wong, J.L.M.; Sim, Y.J.; Wong, S.S.; Elhassan, S.A.M.; Tan, S.H.; Lim, G.P.L.; Tay, N.W.R.; Annan, N.C.; Bhattamisra, S.K. Type 1 and 2 diabetes mellitus: A review on current treatment approach and gene therapy as potential intervention. Diabetes Metab. Syndr. Clin. Res. Rev. 2019, 13, 364–372.
  41. Bruce, K.D.; Hanson, M.A. The developmental origins, mechanisms, and implications of metabolic syndrome. J. Nutr. Biochem. 2010, 140, 648–652.
  42. Oboh, G.; Ademiluyi, A.O.; Akinyemi, A.J.; Henle, T.; Saliu, J.A.; Schwarzenbolz, U. Inhibitory effect of polyphenol-rich extracts of jute leaf (Corchorus olitorius) on key enzyme linked to type 2 diabetes (α-amylase and α-glucosidase) and hypertension (angiotensin I converting) in vitro. J. Funct. Foods 2012, 4, 450–458.
  43. Ganbold, M.; Owada, Y.; Ozawa, Y.; Shimamoto, Y.; Ferdousi, F.; Tominaga, K.; Zheng, Y.-W.; Ohkohchi, N.; Isoda, H. Isorhamnetin alleviates steatosis and fibrosis in mice with nonalcoholic steatohepatitis. Sci. Rep. 2019, 9, 1–11.
  44. Jiang, H.; Yamashita, Y.; Nakamura, A.; Croft, K.; Ashida, H. Quercetin and its metabolite isorhamnetin promote glucose uptake through different signalling pathways in myotubes. Sci. Rep. 2019, 9, 2690.
  45. Lee, D.; Park, J.Y.; Lee, S.; Kang, K.S. In Vitro Studies to Assess the α-Glucosidase Inhibitory Activity and Insulin Secretion Effect of Isorhamnetin 3-O-Glucoside and Quercetin 3-O-Glucoside Isolated from Salicornia herbacea. Processes 2021, 9, 483.
  46. Lee, J.; Jung, E.; Lee, J.; Kim, S.; Huh, S.; Kim, Y.; Kim, Y.; Byun, S.Y.; Kim, Y.S.; Park, D. Isorhamnetin represses adipogenesis in 3T3-L1 cells. Obesity 2009, 17, 226–232.
  47. Manach, C.; Texier, O.; Régérat, F.; Agullo, G.; Demigné, C.; Rémésy, C. Dietary quercetin is recovered in rat plasma as conjugated derivatives of isorhamnetin and quercetin. J. Nutr. Biochem. 1996, 7, 375–380.
  48. Eid, H.M.; Martineau, L.C.; Saleem, A.; Muhammad, A.; Vallerand, D.; Benhaddou-Andaloussi, A.; Nistor, L.; Afshar, A.; Arnason, J.T.; Haddad, P.S. Stimulation of AMP-activated protein kinase and enhancement of basal glucose uptake in muscle cells by quercetin and quercetin glycosides, active principles of the antidiabetic medicinal plant Vaccinium vitis-idaea. Mol. Nutr. Food Res. 2010, 54, 991–1003.
  49. Kalai, F.Z.; Han, J.; Ksouri, R.; Abdelly, C.; Isoda, H. Oral administration of Nitraria retusa ethanolic extract enhances hepatic lipid metabolism in db/db mice model ‘BKS. Cg-Dock7m+/+ Leprdb/J’through the modulation of lipogenesis–lipolysis balance. Food Chem. Toxicol. 2014, 72, 247–256.
  50. Zar Kalai, F.; Han, J.; Ksouri, R.; El Omri, A.; Abdelly, C.; Isoda, H. Antiobesity effects of an edible halophyte Nitraria retusa Forssk in 3T3-L1 preadipocyte differentiation and in C57B6J/L mice fed a high fat diet-induced obesity. Evid.-Based Complement. Altern. Med. 2013, 2013, 368658.
  51. Kim, B.; Choi, Y.E.; Kim, H.S. Eruca sativa and its flavonoid components, quercetin and isorhamnetin, improve skin barrier function by activation of peroxisome proliferator-activated receptor (PPAR)-α and suppression of inflammatory cytokines. Phytother. Res. 2014, 28, 1359–1366.
  52. Lee, M.-K.; Yang, H.-K.; Ha, N.-R.; Sung, S.-H.; Kim, Y.-C. Isorhamnetin from Oenanthe javanica attenuates fibrosis in rat hepatic stellate cells via inhibition of ERK signaling pathway. Nat. Prod. Sci. 2008, 14, 81–85.
  53. Heim, M. The Jak–STAT pathway: Specific signal transduction from the cell membrane to the nucleus. Eur. J. Clin. Investig. 1996, 26, 1–12.
  54. Selvaraj, J. Identification of new antidiabetic agents targeting GLUT4 protein using in silico analysis. Int. J. Green Pharm. 2019, 12, S876.
  55. Eid, H.M.; Nachar, A.; Thong, F.; Sweeney, G.; Haddad, P.S. The molecular basis of the antidiabetic action of quercetin in cultured skeletal muscle cells and hepatocytes. Pharmacogn. Mag. 2015, 11, 74.
  56. Xu, M.; Hu, J.; Zhao, W.; Gao, X.; Jiang, C.; Liu, K.; Liu, B.; Huang, F. Quercetin differently regulates insulin-mediated glucose transporter 4 translocation under basal and inflammatory conditions in adipocytes. Mol. Nutr. Food Res. 2014, 58, 931–941.
  57. Calkin, A.C.; Thomas, M.C. PPAR agonists and cardiovascular disease in diabetes. PPAR Res. 2008, 2008, 245410.
  58. Holm, L.J.; Mønsted, M.Ø.; Haupt-Jorgensen, M.; Buschard, K. PPARs and the development of type 1 diabetes. PPAR Res. 2020, 2020, 6198628.
  59. Lamichane, S.; Dahal Lamichane, B.; Kwon, S.-M. Pivotal roles of peroxisome proliferator-activated receptors (PPARs) and their signal cascade for cellular and whole-body energy homeostasis. Int. J. Mol. Sci. 2018, 19, 949.
  60. Varga, T.; Czimmerer, Z.; Nagy, L. PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochim. Biophys. Acta -Mol. Basis Dis. 2011, 1812, 1007–1022.
  61. Zhang, Y.; Gu, M.; Cai, W.; Yu, L.; Feng, L.; Zhang, L.; Zang, Q.; Wang, Y.; Wang, D.; Chen, H. Dietary component isorhamnetin is a PPARγ antagonist and ameliorates metabolic disorders induced by diet or leptin deficiency. Sci. Rep. 2016, 6, 1–12.
  62. Krishnapuram, R.; Dhurandhar, E.J.; Dubuisson, O.; Hegde, V.; Dhurandhar, N.V. Doxycycline-regulated 3T3-L1 preadipocyte cell line with inducible, stable expression of adenoviral E4orf1 gene: A cell model to study insulin-independent glucose disposal. PLoS ONE 2013, 8, e60651.
  63. Ruiz-Ojeda, F.J.; Rupérez, A.I.; Gomez-Llorente, C.; Gil, A.; Aguilera, C.M. Cell models and their application for studying adipogenic differentiation in relation to obesity: A review. Int. J. Mol. Sci. 2016, 17, 1040.
  64. Lee, J.; Lee, J.; Jung, E.; Hwang, W.; Kim, Y.-S.; Park, D. Isorhamnetin-induced anti-adipogenesis is mediated by stabilization of β-catenin protein. Life Sci. 2010, 86, 416–423.
  65. Farias-Pereira, R.; Savarese, J.; Yue, Y.; Lee, S.-H.; Park, Y. Fat-lowering effects of isorhamnetin are via NHR-49-dependent pathway in Caenorhabditis elegans. Curr. Res. Food Sci. 2020, 2, 70–76.
  66. Sherwin, R.S. Role of liver in glucose homeostasis. Diabetes Care 1980, 3, 261–265.
  67. Roden, M. Mechanisms of disease: Hepatic steatosis in type 2 diabetes—Pathogenesis and clinical relevance. Nat. Clin. Pract. Endocrinol. Metab. 2006, 2, 335–348.
  68. Koyama, Y.; Brenner, D.A. Liver inflammation and fibrosis. J. Clin. Investig. 2017, 127, 55–64.
  69. Marks, J.B.; Raskin, P. Cardiovascular risk in diabetes: A brief review. J. Diabetes Its Complicat. 2000, 14, 108–115.
  70. Marra, F.; Gastaldelli, A.; Baroni, G.S.; Tell, G.; Tiribelli, C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol. Med. 2008, 14, 72–81.
  71. Ahmad, A.; Ahmad, R. Understanding the mechanism of hepatic fibrosis and potential therapeutic approaches. Saudi J. Gastroenterol. 2012, 18, 155.
  72. Sánchez-Valle, V.; Chavez-Tapia, N.C.; Uribe, M.; Méndez-Sánchez, N. Role of oxidative stress and molecular changes in liver fibrosis: A review. Curr. Med. Chem. 2012, 19, 4850–4860.
  73. Shek, F.W.; Benyon, R.C. How can transforming growth factor beta be targeted usefully to combat liver fibrosis? Eur. J. Gastroenterol. Hepatol. 2004, 16, 123–126.
  74. Liu, X.; Hu, H.; Yin, J.Q. Therapeutic strategies against TGF-β signaling pathway in hepatic fibrosis. Liver Int. 2006, 26, 8–22.
  75. Liu, N.; Feng, J.; Lu, X.; Yao, Z.; Liu, Q.; Lv, Y.; Han, Y.; Deng, J.; Zhou, Y. Isorhamnetin inhibits liver fibrosis by reducing autophagy and inhibiting extracellular matrix formation via the TGF-β1/Smad3 and TGF-β1/p38 MAPK pathways. Mediat. Inflamm. 2019, 2019, 6175091.
  76. Katyal, S.; Oliver, J.H., III; Peterson, M.S.; Ferris, J.V.; Carr, B.S.; Baron, R.L. Extrahepatic metastases of hepatocellular carcinoma. Radiology 2000, 216, 698–703.
  77. Singh, M.K.; Das, B.K.; Choudhary, S.; Gupta, D.; Patil, U.K. Diabetes and hepatocellular carcinoma: A pathophysiological link and pharmacological management. Biomed. Pharmacother. 2018, 106, 991–1002.
  78. Yang, J.D.; Ahmed, F.; Mara, K.C.; Addissie, B.D.; Allen, A.M.; Gores, G.J.; Roberts, L.R. Diabetes is associated with increased risk of hepatocellular carcinoma in patients with cirrhosis from nonalcoholic fatty liver disease. Hepatology 2020, 71, 907–916.
  79. Teng, B.-s.; Lu, Y.-H.; Wang, Z.-T.; Tao, X.-Y.; Wei, D.-Z. In vitro anti-tumor activity of isorhamnetin isolated from Hippophae rhamnoides L. against BEL-7402 cells. Pharmacol. Res. 2006, 54, 186–194.
  80. Youness, R.; Assal, R.; Gad, M.; Motaal, A.A. Hijacking hepatocellular carcinoma (HCC) tumour progression through restoring TP53/miR-15a/miR-16 tumour suppressor axis by a novel quercetin glycoside. ESMO Open 2018, 3, A160.
  81. Burganova, G.; Bridges, C.; Thorn, P.; Landsman, L. The Role of Vascular Cells in Pancreatic Beta-Cell Function. Front. Endocrinol. 2021, 12, 442.
  82. Marchetti, P.; Ferrannini, E. International Textbook of Diabetes Mellitus; Wiley-Blackwell: Hoboken, NJ, USA, 2015; Volume 2, p. 1240.
  83. Marchetti, P.; Bugliani, M.; De Tata, V.; Suleiman, M.; Marselli, L. Pancreatic beta cell identity in humans and the role of type 2 diabetes. Front. Cell Dev. Biol. 2017, 5, 55.
  84. Cerf, M.E. Beta cell dysfunction and insulin resistance. Front. Endocrinol. 2013, 4, 37.
  85. Wang, J.-L.; Quan, Q.; Ji, R.; Guo, X.-Y.; Zhang, J.-M.; Li, X.; Liu, Y.-G. Isorhamnetin suppresses PANC-1 pancreatic cancer cell proliferation through S phase arrest. Biomed. Pharmacother. 2018, 108, 925–933.
  86. Grdović, N.; Dinić, S.; Arambašić, J.; Mihailović, M.; Uskoković, A.; Marković, J.; Poznanović, G.; Vidović, S.; Zeković, Z.; Mujić, A. The protective effect of a mix of Lactarius deterrimus and Castanea sativa extracts on streptozotocin-induced oxidative stress and pancreatic β-cell death. Br. J. Nutr. 2012, 108, 1163–1176.
  87. Vessal, M.; Hemmati, M.; Vasei, M. Antidiabetic effects of quercetin in streptozocin-induced diabetic rats. Comp. Biochem. Physiol. Part C Toxicol. Pharmacol. 2003, 135, 357–364.
  88. Coskun, O.; Kanter, M.; Korkmaz, A.; Oter, S. Quercetin, a flavonoid antioxidant, prevents and protects streptozotocin-induced oxidative stress and β-cell damage in rat pancreas. Pharmacol. Res. 2005, 51, 117–123.
  89. Hii, C.; Howell, S. Effects of flavonoids on insulin secretion and 45Ca2+ handling in rat islets of Langerhans. J. Endocrinol. 1985, 107, 1–8.
  90. He, Z.; King, G.L. Microvascular complications of diabetes. Endocrinol. Metab. Clin. 2004, 33, 215–238.
  91. Patel, S.; Santani, D. Role of NF-κB in the pathogenesis of diabetes and its associated complications. Pharmacol. Rep. 2009, 61, 595–603.
  92. Suryavanshi, S.; Kulkarni, Y. NF-κβ: A potential target in the management of vascular complications of diabetes. Front. Pharmacol. 2017, 8, 798.
  93. Singh, V.P.; Bali, A.; Singh, N.; Jaggi, A.S. Advanced glycation end products and diabetic complications. Korean J. Physiol. Pharmacol. 2014, 18, 1–14.
  94. Leo, C.-H.; Woodman, O.L. Flavonols in the prevention of diabetes-induced vascular dysfunction. J. Cardiovasc. Pharmacol. 2015, 65, 532.
  95. Hämäläinen, M.; Nieminen, R.; Vuorela, P.; Heinonen, M.; Moilanen, E. Anti-inflammatory effects of flavonoids: Genistein, kaempferol, quercetin, and daidzein inhibit STAT-1 and NF-κB activations, whereas flavone, isorhamnetin, naringenin, and pelargonidin inhibit only NF-κB activation along with their inhibitory effect on iNOS expression and NO production in activated macrophages. Mediat. Inflamm. 2007, 2007, 045673.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
ScholarVision Creations
Feedback